Acute coronary syndromes: advances in antithrombotics

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute coronary syndromes (ACS) management has advanced with revascularization and antithrombotic therapies.
• Despite progress, significant rates of recurrent ischemic and bleeding events persist, particularly post-percutaneous coronary intervention (PCI).

Purpose of the Study:

• To review recent advances in ACS pharmacotherapy.
• To discuss clinical trials evaluating novel antiplatelet drugs and novel oral anticoagulants (NOACs).
• To explore challenges in interpreting and implementing findings from these trials.

Main Methods:

• Literature review of contemporary ACS management.
• Analysis of recent clinical trials on potent antiplatelet agents (prasugrel, ticagrelor, PAR-1 inhibitors) and NOACs.
• Discussion of pharmacologic strategies to balance ischemic risk reduction and bleeding limitation.

Main Results:

• Newer antiplatelet drugs and NOACs are being evaluated to improve outcomes post-PCI.
• Balancing the reduction of recurrent ischemia against iatrogenic bleeding remains a key clinical dilemma.
• Optimal anticoagulation regimens are crucial for managing ACS patients.

Conclusions:

• Ongoing research focuses on optimizing pharmacotherapy for ACS to minimize both ischemic and bleeding complications.
• Careful interpretation and implementation of trial data are essential for effective patient management.
• The ideal anticoagulation strategy post-PCI requires further refinement.